Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (CDNK333B2201)

This study has been completed.
Information provided by:
Novartis Identifier:
First received: June 12, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2005
  Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)